Case Report: Paratesticular Rhabdomyosarcoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Apr 5

PMID 33816267

Citations 4

Authors

Yiyi Zhu

Ziwei Zhu

Yunyuan Xiao

Zaisheng Zhu

Affiliations

Soon will be listed here.

Abstract

Paratesticular rhabdomyosarcoma (RMS) accounts for only 7% of all the RMS cases. Due to the limited available data, there is no consensus on the diagnosis and management of the paratesticular tumors. Here, we interrogated two paratesticular RMS cases in 25 and 27-year-old men presenting with painless and rapidly growing mass in the scrotum. Whereas the data showed no upregulation of tumor markers such as -human chorionic gonadotropin (-HCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH), scrotal ultrasonography and magnetic resonance imaging indicated the existence of paratesticular and inguinal lesions respectively. There was local recurrence in one patient who underwent radical orchiectomy for the sarcoma one year ago. In addition, the CT scans showed no occurrence of distant metastasis. The two patients underwent radical inguinal orchiectomy or resection of the recurrent tumors with nerve-sparing retroperitoneal lymph node dissection. Histologic examination revealed embryonal RMS (eRMS) without lymph node metastasis. We highlight the importance of multi-disciplinary participation for paratesticular RMS detection and preoperative ultrasound-guided needle biopsy (UNB) for rapid confirmatory diagnosis. Complete surgical resection coupled with chemotherapy and radiotherapy is the main treatment option for the paratesticular RMS. In addition, sperm cryopreservation treatment and endocrine follow-up could increase the overall survival and quality of life of the patients.

Citing Articles

Alveolar Paratesticular Rhabdomyosarcoma in an Adult Patient With PAX3-FOXO1 Fusion and Unfavorable Evolution.

Paese E, Rodriguez R, Azambuja A Cureus. 2024; 16(10):e71279.

PMID: 39529773 PMC: 11551073. DOI: 10.7759/cureus.71279.

Primary paratesticular embryonal rhabdomyosarcoma - An unusual presentation.

Singh P, Anandani G, Parmar R J Family Med Prim Care. 2023; 12(9):2176-2180.

PMID: 38024875 PMC: 10657067. DOI: 10.4103/jfmpc.jfmpc_397_23.

A case report of primary para-testicular spindle cell rhabdomyosarcoma.

Su P, Yang Y, Wang X, Chen S, Zhang N, Yang H Front Oncol. 2023; 13:1166503.

PMID: 37350935 PMC: 10282740. DOI: 10.3389/fonc.2023.1166503.

Surgical resection of a massive residual retroperitoneal mass after chemotherapy for a paratesticular rhabdomyosarcoma: a case report.

Chalouati T, Ghalleb M, Jallali A, Slimane M, Sahraoui G, Ben Hassouna J J Med Case Rep. 2022; 16(1):476.

PMID: 36550579 PMC: 9783374. DOI: 10.1186/s13256-022-03707-x.

References

Harel M, Ferrer F, Shapiro L, Makari J . Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma. Urol Oncol. 2015; 34(2):103-15. DOI: 10.1016/j.urolonc.2015.09.013. View

Rogers T, Minard-Colin V, Cozic N, Jenney M, Merks J, Gallego S . Paratesticular rhabdomyosarcoma in children and adolescents-Outcome and patterns of relapse when utilizing a nonsurgical strategy for lymph node staging: Report from the International Society of Paediatric Oncology (SIOP) Malignant Mesenchymal.... Pediatr Blood Cancer. 2017; 64(9). DOI: 10.1002/pbc.26486. View

Visser M, Sijmons C, Bras J, Arceci R, Godfried M, Valentijn L . Allelotype of pediatric rhabdomyosarcoma. Oncogene. 1997; 15(11):1309-14. DOI: 10.1038/sj.onc.1201302. View

Cerda T, Martin E, Truc G, Crehange G, Maingon P . Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma. Cancer Radiother. 2017; 21(1):16-20. DOI: 10.1016/j.canrad.2016.07.102. View

Rodriguez D, Olumi A . Management of spermatic cord tumors: a rare urologic malignancy. Ther Adv Urol. 2012; 4(6):325-34. PMC: 3491755. DOI: 10.1177/1756287212447839. View

Stewart R, Martelli H, Oberlin O, Rey A, Bouvet N, Spicer R . Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J Clin Oncol. 2003; 21(5):793-8. DOI: 10.1200/JCO.2003.06.040. View

Akbar S, Sayyed T, Jafri S, Hasteh F, Neill J . Multimodality imaging of paratesticular neoplasms and their rare mimics. Radiographics. 2003; 23(6):1461-76. DOI: 10.1148/rg.236025174. View

Frates M, Benson C, DiSalvo D, Brown D, Laing F, Doubilet P . Solid extratesticular masses evaluated with sonography: pathologic correlation. Radiology. 1997; 204(1):43-6. DOI: 10.1148/radiology.204.1.9205221. View

Hammond W, Farber B, Price A, Wolden S, Heaton T, Wexler L . Paratesticular rhabdomyosarcoma: Importance of initial therapy. J Pediatr Surg. 2016; 52(2):304-308. PMC: 5253324. DOI: 10.1016/j.jpedsurg.2016.11.027. View

10.

Terezakis S, Wharam M . Radiotherapy for rhabdomyosarcoma: indications and outcome. Clin Oncol (R Coll Radiol). 2012; 25(1):27-35. DOI: 10.1016/j.clon.2012.07.009. View

11.

Fagundes M, Zietman A, Althausen A, Coen J, Shipley W . The management of spermatic cord sarcoma. Cancer. 1996; 77(9):1873-6. DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1873::AID-CNCR17>3.0.CO;2-X. View

12.

Weiss A, Lyden E, Anderson J, Hawkins D, Spunt S, Walterhouse D . Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol. 2013; 31(26):3226-32. PMC: 3757291. DOI: 10.1200/JCO.2012.44.6476. View

13.

Graiouid E, Chakir Y, Gallouo M, Dakir M, Debbagh A, Aboutaieb R . [Paratesticular rhabdomyosarcoma: a case report]. Pan Afr Med J. 2019; 33:55. PMC: 6690064. DOI: 10.11604/pamj.2019.33.55.17269. View

14.

Alanee S, Holland B, Dynda D, Kamel O, Ganai S . Primary tumor size predicts pathologic findings in the retroperitoneal lymph nodes in patients with paratesticular rhabdomyosarcoma. Virchows Arch. 2014; 465(6):697-701. DOI: 10.1007/s00428-014-1663-x. View

15.

Dangle P, Correa A, Tennyson L, Gayed B, Reyes-Mugica M, Ost M . Current management of paratesticular rhabdomyosarcoma. Urol Oncol. 2015; 34(2):84-92. DOI: 10.1016/j.urolonc.2015.10.004. View

16.

Mak C, Chou C, Su C, Huan S, Chang J . Ultrasound diagnosis of paratesticular rhabdomyosarcoma. Br J Radiol. 2004; 77(915):250-2. DOI: 10.1259/bjr/20564274. View

17.

Walterhouse D, Lyden E, Breitfeld P, Qualman S, Wharam M, Meyer W . Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol. 2004; 22(8):1398-403. DOI: 10.1200/JCO.2004.05.184. View

18.

Dang N, Dang P, Samuelian J, Paulino A . Lymph node management in patients with paratesticular rhabdomyosarcoma: a population-based analysis. Cancer. 2013; 119(17):3228-33. DOI: 10.1002/cncr.28198. View

19.

NEWTON Jr W, Gehan E, Webber B, Marsden H, van Unnik A, Hamoudi A . Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study. Cancer. 1995; 76(6):1073-85. DOI: 10.1002/1097-0142(19950915)76:6<1073::aid-cncr2820760624>3.0.co;2-l. View

20.

Faure A, Diakite M, Panait N, Chaumoitre K, Rome A, Merrot T . [Paratesticular rhabdomyosarcoma in children: a scrotal emergency]. Arch Pediatr. 2012; 19(12):1340-4. DOI: 10.1016/j.arcped.2012.09.022. View